Product How it works Pricing Blog FAQ About Contact
Dianthus Therapeutics

Dianthus Therapeutics (NASDAQ: DNTH) revenue

Dianthus Therapeutics reported revenue of $16.1m for fiscal 2025, 7.2% less than in fiscal 2024 ($17.4m).

Dianthus Therapeutics's best year of the last 6 was fiscal 2024. The biggest drop was in fiscal 2025, −7.2%.

Revenue, in millions of US dollars0.020170.020180.020194.8202317.4202416.12025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$16.1m−7.2%−$177.9m−1,103.9%
2024$17.4m+264.5%−$101.9m−586.6%
2023$4.8m—−$48.2m−1,011.2%
2019$0.0m—−$83.0m—
2018$0.0m—−$60.0m—
2017$0.0m—−$35.7m—

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Dianthus Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, Dianthus Therapeutics ranks 357th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Dianthus Therapeutics, −7.2%.

RankCompanyRevenueRevenue growth
355thLENZ Therapeutics$19.1m—
356thOmniab$18.7m−29.3%
357thDianthus Therapeutics$16.1m−7.2%
358thRelay Therapeutics$15.4m53.4%
359thLineage Cell Therapeutics$14.6m53.2%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Dianthus Therapeutics

How much revenue did Dianthus Therapeutics make in fiscal 2025?
Dianthus Therapeutics reported revenue of $16.1m for fiscal 2025, compared with $17.4m in fiscal 2024.
What was the best year for revenue at Dianthus Therapeutics?
Of its last 6 fiscal years, fiscal 2024, with $17.4m.
Where does Dianthus Therapeutics rank in its sector by revenue?
It ranks 357th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Dianthus Therapeutics come from?
From the annual report (Form 10-K) that Dianthus Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Dianthus Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2019 · 2018 · 2017. More on Dianthus Therapeutics: the Dianthus Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.